Loading chat...
NY S01618
Bill
Status
Engrossed
5/20/2025
Primary Sponsor
Gustavo Rivera
Click for details
AI Summary
- Directs the Commissioner of Health to enter into partnerships with drug companies, other states, and various entities to manufacture and distribute generic prescription drugs at lower prices
- Requires partnerships to include production of at least one form of insulin if a viable manufacturing pathway exists, with priority given to drugs for chronic and high-cost conditions
- Mandates all state agencies purchase generic prescription drugs from the department or its partner entities
- Requires the department to consult with state agencies, health insurers, hospitals, and other purchasers to develop a list of targeted drugs and determine procurement volumes over multiyear periods
- Establishes reporting requirements including a feasibility study on direct state manufacturing due January 1, 2028, and a status report on targeted drugs due March 1, 2027
Legislative Description
Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Last Action
referred to health
2/24/2026
Committee Referrals
Health2/24/2026
Rules2/9/2026
Finance2/4/2026
Health1/7/2026
Health5/20/2025
Finance1/21/2025
Health1/13/2025
Full Bill Text
No bill text available